Trial reportIntensive care medicine2006
Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia.
Trial report in Intensive care medicine, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 73 citations in OpenAlex.
- Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial.Critical care (London, England) · 2020Trial
- Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects.Antimicrobial agents and chemotherapy · 2018Trial
- Penetration of ertapenem into muscle measured by in vivo microdialysis in mechanically ventilated patients.Antimicrobial agents and chemotherapy · 2011Trial
- Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia.Antimicrobial agents and chemotherapy · 2011Trial
- Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients.Antimicrobial agents and chemotherapy · 2010Trial
- Ten-Year Evaluation of Ventilator-Associated Pneumonia (VAP) According to Initial Empiric Treatment: A Retrospective Analysis Using Real-World Data.Biomedicines · 2025Article
- Artificial Intelligence to Close the Gap between Pharmacokinetic/Pharmacodynamic Targets and Clinical Outcomes in Critically Ill Patients: A Narrative Review on Beta Lactams.Antibiotics (Basel, Switzerland) · 2024Review
- Ertapenem's therapeutic potential for Mycobacterium avium lung disease in the hollow fibre model.International journal of antimicrobial agents · 2024Article
- Tissue Penetration of Antimicrobials in Intensive Care Unit Patients: A Systematic Review-Part I.Antibiotics (Basel, Switzerland) · 2022Review
- Modelled Target Attainment after Temocillin Treatment in Severe Pneumonia: Systemic and Epithelial Lining Fluid Pharmacokinetics of Continuous versus Intermittent Infusions.Antimicrobial agents and chemotherapy · 2022Article
- Penetration of Antibacterial Agents into Pulmonary Epithelial Lining Fluid: An Update.Clinical pharmacokinetics · 2022Review
- Beta-Lactams Dosing in Critically Ill Patients with Gram-Negative Bacterial Infections: A PK/PD Approach.Antibiotics (Basel, Switzerland) · 2021Review
- Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.Antimicrobial agents and chemotherapy · 2019Article
- Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients.Critical care (London, England) · 2018Review
- Population Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery.Antimicrobial agents and chemotherapy · 2017Article
- Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Clinical therapeutics · 2016Review
- Community-acquired pneumonia: identification and evaluation of nonresponders.Therapeutic advances in infectious disease · 2013Review
- Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.Annals of intensive care · 2012Article
- Determination of meropenem penetration into the lung from Sparse data.Antimicrobial agents and chemotherapy · 2011Article
- Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.Clinical pharmacokinetics · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe conducted a prospective, open-label study to determine the steady-state serum and epithelial lining fluid (ELF) concentrations of unbound ertapenem administered once daily to critically ill patients with early-onset ventilator-associated pneumonia (VAP). DESIGN AND
settingProspective, open-label study in an intensive care unit and research ward in a university hospital. PATIENTS: Fifteen patients with VAP received 1-h intravenous infusions of 1 g ertapenem once daily.
interventionsAfter 2 days of therapy the steady-state serum and ELF concentrations of free ertapenem were determined by high-performance liquid chromatography. MEASUREMENTS AND
resultsThe median (interquartile range) free ertapenem peak (C(max)), intermediate (C(12)), and trough (C(min)) concentrations (mg/l) 1, 12, and 24 h after the end of infusion were 30.3 (27.1-37.8), 4.8 (3.9-6.4), and 0.8 (0.5-1.2) in serum and 9.4 (8.0-10.7), 2.0 (1.1-2.5), and 0.3 (0.2-0.4) in ELF, respectively, showing a median free ertapenem percentage penetration in ELF of approx. 30%. The median (interquartile range) serum area under concentration-time curve of free ertapenem during the observational period was 226.7 mg h(-1) l(-1) (202.2-263.9).
conclusionOur study shows satisfactory results, with unbound ertapenem concentrations both in serum and ELF exceeding the MIC(90) values of most of the causative pathogens encountered in early-onset VAP during 50-100% time. This suggests that 1 g intravenous ertapenem administered once daily should be effective during the treatment of early-onset VAP in critically ill patients with no known risk factors for multidrug-resistant pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.